GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fleury SA (BSP:FLRY3) » Definitions » EBIT

Fleury (BSP:FLRY3) EBIT : R$1,318 Mil (TTM As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Fleury EBIT?

Fleury's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was R$251 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was R$1,318 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fleury's annualized ROC % for the quarter that ended in Dec. 2024 was 6.68%. Fleury's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 30.45%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fleury's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 13.86%.


Fleury EBIT Historical Data

The historical data trend for Fleury's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fleury EBIT Chart

Fleury Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 487.80 689.83 818.55 1,008.65 1,318.09

Fleury Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 216.50 331.19 348.98 387.16 250.76

Competitive Comparison of Fleury's EBIT

For the Diagnostics & Research subindustry, Fleury's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fleury's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fleury's EV-to-EBIT falls into.


;
;

Fleury EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fleury  (BSP:FLRY3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fleury's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=836.36 * ( 1 - 21.39% )/( (9895.353 + 9802.172)/ 2 )
=657.462596/9848.7625
=6.68 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13031.228 - 1014.74 - ( 2235.215 - max(0, 2271.091 - 4392.226+2235.215))
=9895.353

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13062.41 - 918.495 - ( 2341.743 - max(0, 1742.813 - 4375.794+2341.743))
=9802.172

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Fleury's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1003.052/( ( (2493.989 + max(791.381, 0)) + (2513.708 + max(788.849, 0)) )/ 2 )
=1003.052/( ( 3285.37 + 3302.557 )/ 2 )
=1003.052/3293.9635
=30.45 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1763.847 + 139.511 + 253.653) - (1014.74 + 0 + 350.89)
=791.381

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1634.904 + 155.036 + 244.111) - (918.495 + 0 + 326.707)
=788.849

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fleury's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=1318.091/9512.263
=13.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fleury EBIT Related Terms

Thank you for viewing the detailed overview of Fleury's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Fleury Business Description

Traded in Other Exchanges
N/A
Address
Avenida Morumbi 8.860, Itaim Bibi, Sao Paulo, SP, BRA, 4344903
Fleury SA is engaged in the provision of medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics and ophthalmology areas and offers its digital healthcare platform. The company carries out its activities through customer service units and hospital-based units. Furthermore, the company has a mobile service operation with coverage in municipalities in addition to a digital platform. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from Diagnostic Medicine Segment.

Fleury Headlines

No Headlines